CyPath® Lung detected a Stage 1A neuroendocrine tumor in a patient's lung when imaging and other adjuvant tools could not.

Insmed stock is soaring as it approaches the potential approval of its second drug. CEO Will Lewis calls it a "skeleton key." ...

The new inhaler replaces Trixeo Aerosphere’s existing gas propellant with a low global warming-potential alternative.

Avalyn Pharma has drawn in another fundraising round, this time a $100 million oversubscribed series D to continue developing ...

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

European regulators have given their backing to a new eco-friendly inhaler that could help curb health care’s climate impact.

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Following up on the $175 million it raised in September 2023, Avalyn Pharma Inc. secured an additional $100 million in an ...